| Literature DB >> 33668707 |
Shivkanya Fuloria1, Vetriselvan Subramaniyan2, Rajiv Dahiya3, Sunita Dahiya4, Kalvatala Sudhakar5, Usha Kumari6, Kathiresan Sathasivam7, Dhanalekshmi Unnikrishnan Meenakshi8, Yuan Seng Wu2, Mahendran Sekar9, Rishabha Malviya10, Amit Singh10, Neeraj Kumar Fuloria1.
Abstract
Evidence suggests that stem cells exert regenerative potential via the release of extracellular vesicles. Mesenchymal stem cell extracellular vesicles (MSCEVs) offer therapeutic benefits for various pathophysiological ailments by restoring tissues. Facts suggest that MSCEV action can be potentiated by modifying the mesenchymal stem cells culturing methodology and bioengineering EVs. Limited clinical trials of MSCEVs have questioned their superiority, culturing quality, production scale-up and isolation, and administration format. Translation of preclinically successful MSCEVs into a clinical platform requires paying attention to several critical matters, such as the production technique, quantification/characterization, pharmacokinetics/targeting/transfer to the target site, and the safety profile. Keeping these issues as a priority, the present review was designed to highlight the challenges in translating preclinical MSCEV research into clinical platforms and provide evidence for the regenerative potential of MSCEVs in various conditions of the liver, kidney, heart, nervous system, bone, muscle, cartilage, and other organs/tissues.Entities:
Keywords: cell injury; extracellular vesicles; regenerative potential; stem cells; therapeutics
Year: 2021 PMID: 33668707 PMCID: PMC7996168 DOI: 10.3390/biology10030172
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737